-
<![CDATA[Apalutamide/ADT Improves Long-Term Outcomes in Biochemically Recurrent Prostate Cancer]]>
19 Oct 2025 19:43 GMT
… -resistant prostate cancer (CRPC), prostate-specific antigen progression-free survival (PSA-PFS) … with biochemically recurrent prostate cancer with a short PSA doubling time … therapy for oligometastatic, metachronous prostate cancer remains to be defined …
-
This Powerful Drug Combo Cuts Prostate Cancer Deaths by 40%
19 Oct 2025 17:12 GMT
… biochemically recurrent prostate cancer, a condition where prostate specific antigen (PSA) levels rise … radiation. PSA is a protein used to monitor prostate cancer activity, … with high-risk biochemically recurrent prostate cancer.
"These important …
-
<![CDATA[Truqap Extends Radiographic Progression-Free Survival in Some With Prostate Cancer]]>
19 Oct 2025 20:04 GMT
… de novo metastatic hormone-sensitive prostate cancer, according to results presented at … for placebo. Median time to PSA progression was not calculable at … Truqap in metastatic castration-resistant prostate cancer. News release. AstraZeneca. April 29 …
-
Renowned Journalist Rajdeep Sardesai Opens Up About His Battle With Prostate Cancer: Know Symptoms, Causes & Treatment
19 Oct 2025 15:16 GMT
… personal battle with prostate cancer, sharing a deeply … rate.
Understanding prostate cancer
Prostate cancer develops in the prostate gland, … exact cause of prostate cancer, but certain risk … early detection through PSA (Prostate-Specific Antigen) blood tests …
-
Drug combo cuts risk of death in advanced prostate cancer by 40%
19 Oct 2025 15:03 GMT
… in patients with recurrent prostate cancer after surgery or … high-risk biochemically recurrent prostate cancer. Following the patients’ … rapidly. PSA is a protein used to detect prostate cancer, and … a rapid rise in PSA levels …
-
<![CDATA[EMBARK data indicate large OS benefit with enzalutamide/ADT in prostate cancer]]>
19 Oct 2025 15:02 GMT
… with biochemically recurrent prostate cancer, combination treatment with … would resume if PSA levels reached predefined … antineoplastic therapies for prostate cancer, symptomatic skeletal events … , biochemically recurrent prostate cancer patients.”
DISCLOSURES: …
-
<![CDATA[Capivasertib prolongs rPFS in PTEN-deficient hormone-sensitive prostate cancer]]>
19 Oct 2025 15:02 GMT
… as radiographic disease progression, PSA progression, and development of … The median time to PSA progression was not calculable … curves for time to PSA progression defined by … Truqap in metastatic castration-resistant prostate cancer. News release. AstraZeneca. …
-
XTANDI® Plus Leuprolide Reduced Risk of Death by 40% vs Leuprolide Alone in Men with a Type of Advanced Prostate Cancer
19 Oct 2025 09:15 GMT
… BCR disease had a prostate-specific antigen (PSA) doubling time ≤ 9 months … -resistant prostate cancer (CRPC)
metastatic castration-sensitive prostate cancer (mCSPC)
nonmetastatic castration sensitive prostate cancer (nmCSPC …
-
New Drug Combination Reduces Mortality Risk in Advanced Prostate Cancer by 40%
19 Oct 2025 09:25 GMT
… Medicine
Keywords: Prostate cancer, Cancer, Biochemically recurrent prostate cancer, Enzalutamide, Hormone therapy, Clinical trial, PSA, Metastatic …
-
Our ultimate guide to the pros and cons of prostate cancer screening: We reveal why some doctors are opposed to mass testing, who SHOULD ask for a check and the truth about the risks
18 Oct 2025 16:09 GMT
… battle with prostate cancer
Q Screening for prostate cancer seems to … of death from prostate cancer by having regular PSA tests.
‘And the … deter men from seeking a PSA test, says Professor James.
… high-risk criteria, regular PSA testing may be less essential, …
About
© 1995-2025